Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial

Final part 1 analysis of GMMG-HD7 (331 Isa-RVd, 329 RVd). MRD-negativity rates continued to deepen after transplant (66% Isa-RVd vs 48% RVd). Isa-RVd induction significantly prolonged PFS vs RVd regardless of maintenance (HR 0.70, 95% CI 0.52-0.95, P=0.0184). Level 2 (MRD and PFS analysis of a randomized trial).

J Clin OncolPubMed 39652594